Advertisement

Journal of Hepato-Biliary-Pancreatic Surgery

, Volume 16, Issue 2, pp 101–112 | Cite as

Current status of islet cell transplantation

  • Hirohito Ichii
  • Camillo Ricordi
Topics HBP treatment using cell transplantation in the near future

Abstract

Despite substantial advances in islet isolation methods and immunosuppressive protocol, pancreatic islet cell transplantation remains an experimental procedure currently limited to the most severe cases of type 1 diabetes mellitus. The objectives of this treatment are to prevent severe hypoglycemic episodes in patients with hypoglycemia unawareness and to achieve a more physiological metabolic control. Insulin independence and long term-graft function with improvement of quality of life have been obtained in several international islet transplant centers. However, experimental trials of islet transplantation clearly highlighted several obstacles that remain to be overcome before the procedure could be proposed to a much larger patient population. This review provides a brief historical perspective of islet transplantation, islet isolation techniques, the transplant procedure, immunosuppressive therapy, and outlines current challenges and future directions in clinical islet transplantation.

Keywords

Islet cell transplantation Immuonsuppresive protocol Pancreatic islet cells Hypoglycemic 

Notes

Acknowledgments

The authors are grateful to the members of the Human Cell Processing Facility, Preclinical Cell Processing Laboratory of the Cell Transplant Center, Clinical Islet Transplant Program, General Clinical Research Center, Imaging Core at the Diabetes Research Institute, Administrative Offices at the Diabetes Research Institute, and Organ Procurement Organizations for the continuous enthusiasm and support to our program. This work was supported in part by NIH-NCRR, GCRC MO1RR16587, NIDDK RO1-DK55347-IU42RR016603, 5R01 DK25802, ICR 5U42RR016603, JDRFI 4-200-946 and 4-2004-361, and the Diabetes Research Institute Foundation.

References

  1. 1.
    Larsen CE, Alper CA. The genetics of HLA-associated disease. Curr Opin Immunol. 2004;16(5):660.PubMedGoogle Scholar
  2. 2.
    Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg. 2001;25(4):487.PubMedGoogle Scholar
  3. 3.
    Stratta RJ. Late acute rejection episodes after vascularized pancreas transplantation. Transplant Proc. 1998;30(4):1560.PubMedGoogle Scholar
  4. 4.
    Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol. 2004;4(4):259.PubMedGoogle Scholar
  5. 5.
    Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336(8712):402.PubMedGoogle Scholar
  6. 6.
    Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230.PubMedGoogle Scholar
  7. 7.
    Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet. 2003;362(9391):1242.PubMedGoogle Scholar
  8. 8.
    Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955.PubMedGoogle Scholar
  9. 9.
    O’Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolation. Transplant Proc. 2005;37(2):1309.PubMedGoogle Scholar
  10. 10.
    Zeng Y, Torre MA, Karrison T, Thistlethwaite JR. The correlation between donor characteristics and the success of human islet isolation. Transplantation. 1994;57(6):954.PubMedGoogle Scholar
  11. 11.
    Brandhorst H, Brandhorst D, Hering BJ, Federlin K, Bretzel RG. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes. 1995;103(Suppl 2):23.PubMedGoogle Scholar
  12. 12.
    Lakey JR, Warnock GL, Rajotte RV, et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation. 1996;61(7):1047.PubMedGoogle Scholar
  13. 13.
    Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant. 2007;16(6):595.PubMedGoogle Scholar
  14. 14.
    Ris F, Toso C, Veith FU, Majno P, Morel P, Oberholzer J. Are criteria for islet and pancreas donors sufficiently different to minimize competition? Am J Transplant. 2004;4(5):763.PubMedGoogle Scholar
  15. 15.
    Ricordi C. Quantitative and qualitative standards for islet isolation assessment in humans and large mammals. Pancreas. 1991;6(2):242.PubMedGoogle Scholar
  16. 16.
    Ihm SH, Matsumoto I, Sawada T, et al. Effect of donor age on function of isolated human islets. Diabetes. 2006;55(5):1361.PubMedGoogle Scholar
  17. 17.
    Balamurugan AN, Chang Y, Bertera S, et al. Suitability of human juvenile pancreatic islets for clinical use. Diabetologia. 2006;49(8):1845.PubMedGoogle Scholar
  18. 18.
    Nano R, Clissi B, Melzi R, et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia. 2005;48(5):906.PubMedGoogle Scholar
  19. 19.
    Toso C, Oberholzer J, Ris F, et al. Factors affecting human islet of Langerhans isolation yields. Transplant Proc. 2002;34(3):826.PubMedGoogle Scholar
  20. 20.
    Alderson D, Kneteman NM, Scharp DW. The isolation of purified human islets of Langerhans. Transplant Proc. 1987;19(1 Pt 2):916.PubMedGoogle Scholar
  21. 21.
    Powner DJ. Donor care before pancreatic tissue transplantation. Prog Transplant. 2005;15(2):129.PubMedGoogle Scholar
  22. 22.
    Sakuma Y, Ricordi C, Miki A, et al. Factors that affect human islet isolation. Transplant Proc. 2008;40(2):343.PubMedGoogle Scholar
  23. 23.
    D’Alessandro AM, Stratta RJ, Sollinger HW, Kalayoglu M, Pirsch JD, Belzer FO. Use of UW solution in pancreas transplantation. Diabetes. 1989;38(Suppl 1):7.PubMedGoogle Scholar
  24. 24.
    Munn SR, Kaufman DB, Field MJ, Viste AB, Sutherland DE. Cold-storage preservation of the canine and rat pancreas prior to islet isolation. Transplantation. 1989;47(1):28.PubMedGoogle Scholar
  25. 25.
    Kuroda Y, Kawamura T, Suzuki Y, Fujiwara H, Yamamoto K, Saitoh Y. A new, simple method for cold storage of the pancreas using perfluorochemical. Transplantation. 1988;46(3):457.PubMedGoogle Scholar
  26. 26.
    Matsumoto S, Qualley SA, Goel S, et al. Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. Transplantation. 2002;74(10):1414.PubMedGoogle Scholar
  27. 27.
    Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation. 2002;74(12):1687.PubMedGoogle Scholar
  28. 28.
    Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation. 2003;75(9):1524.PubMedGoogle Scholar
  29. 29.
    Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4(3):390.PubMedGoogle Scholar
  30. 30.
    Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413.PubMedGoogle Scholar
  31. 31.
    Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318.PubMedGoogle Scholar
  32. 32.
    Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037.PubMedGoogle Scholar
  33. 33.
    Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830.PubMedGoogle Scholar
  34. 34.
    Alejandro R, Strasser S, Zucker PF, Mintz DH. Isolation of pancreatic islets from dogs. Semiautomated purification on albumin gradients. Transplantation. 1990;50(2):207.PubMedGoogle Scholar
  35. 35.
    Lake SP, Bassett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(Suppl 1):143.PubMedGoogle Scholar
  36. 36.
    Linetsky E, Bottino R, Lehmann R, Alejandro R, Inverardi L, Ricordi C. Improved human islet isolation using a new enzyme blend, liberase. Diabetes. 1997;46(7):1120.PubMedGoogle Scholar
  37. 37.
    Kin T, Johnson PR, Shapiro AM, Lakey JR. Factors influencing the collagenase digestion phase of human islet isolation. Transplantation. 2007;83(1):7.PubMedGoogle Scholar
  38. 38.
    Johnson PR, White SA, London NJ. Collagenase and human islet isolation. Cell Transplant. 1996;5(4):437.PubMedGoogle Scholar
  39. 39.
    Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes. 2003;52(5):1143.PubMedGoogle Scholar
  40. 40.
    Brandhorst H, Brandhorst D, Hering BJ, Bretzel RG. Significant progress in porcine islet mass isolation utilizing liberase HI for enzymatic low-temperature pancreas digestion. Transplantation. 1999;68(3):355.PubMedGoogle Scholar
  41. 41.
    Bucher P, Mathe Z, Morel P, et al. Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation. 2005;79(1):91.PubMedGoogle Scholar
  42. 42.
    Barnett MJ, Zhai X, LeGatt DF, Cheng SB, Shapiro AM, Lakey JR. Quantitative assessment of collagenase blends for human islet isolation. Transplantation. 2005;80(6):723.PubMedGoogle Scholar
  43. 43.
    Yamamoto T, Ricordi C, Messinger S, et al. Deterioration and variability of highly purified collagenase blends used in clinical islet isolation. Transplantation. 2007;84(8):997.PubMedGoogle Scholar
  44. 44.
    Antonioli B, Fermo I, Cainarca S, et al. Characterization of collagenase blend enzymes for human islet transplantation. Transplantation. 2007;84(12):1568.PubMedGoogle Scholar
  45. 45.
    Kin T, Zhai X, Murdoch TB, Salam A, Shapiro AM, Lakey JR. Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant. 2007;7(5):1233.PubMedGoogle Scholar
  46. 46.
    Chadwick DR, Robertson GS, Toomey P, et al. Pancreatic islet purification using bovine serum albumin: the importance of density gradient temperature and osmolality. Cell Transplant. 1993;2(4):355.PubMedGoogle Scholar
  47. 47.
    Goto M, Eich TM, Felldin M, et al. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation. 2004;78(9):1367.PubMedGoogle Scholar
  48. 48.
    Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg. 2003;237(6):741.PubMedGoogle Scholar
  49. 49.
    Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant. 2005;5(1):21.PubMedGoogle Scholar
  50. 50.
    Matsumoto S, Noguchi H, Yonekawa Y, et al. Pancreatic islet transplantation for treating diabetes. Expert Opin Biol Ther. 2006;6(1):23.PubMedGoogle Scholar
  51. 51.
    Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation. 1991;51(1):76.PubMedGoogle Scholar
  52. 52.
    Alejandro R, Feldman EC, Shienvold FL, Mintz DH. Advances in canine diabetes mellitus research: etiopathology and results of islet transplantation. J Am Vet Med Assoc. 1988;193(9):1050.PubMedGoogle Scholar
  53. 53.
    Alejandro R, Cutfield RG, Shienvold FL, et al. Natural history of intrahepatic canine islet cell autografts. J Clin Invest. 1986;78(5):1339.PubMedGoogle Scholar
  54. 54.
    Warnock GL, Kneteman NM, Ryan EA, Rabinovitch A, Rajotte RV. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(1):89.PubMedGoogle Scholar
  55. 55.
    Goss JA, Schock AP, Brunicardi FC, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation. 2002;74(12):1761.PubMedGoogle Scholar
  56. 56.
    Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060.PubMedGoogle Scholar
  57. 57.
    Warnock GL, Meloche RM, Thompson D, et al. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs. best medical therapy in type 1 diabetes mellitus. Arch Surg. 2005;140(8):735.PubMedGoogle Scholar
  58. 58.
    Holmes MA, Clayton HA, Chadwick DR, Bell PR, London NJ, James RF. Functional studies of rat, porcine, and human pancreatic islets cultured in ten commercially available media. Transplantation. 1995;60(8):854.PubMedGoogle Scholar
  59. 59.
    Murdoch TB, McGhee-Wilson D, Shapiro AM, Lakey JR. Methods of human islet culture for transplantation. Cell Transplant. 2004;13(6):605.PubMedGoogle Scholar
  60. 60.
    Abdelli S, Ansite J, Roduit R, et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes. 2004;53(11):2815.PubMedGoogle Scholar
  61. 61.
    Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes. 2004;53(10):2559.PubMedGoogle Scholar
  62. 62.
    Matsuda T, Omori K, Vuong T, et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant. 2005;5(3):484.PubMedGoogle Scholar
  63. 63.
    Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes. 2005;54(6):1755.PubMedGoogle Scholar
  64. 64.
    Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360(9350):2039.PubMedGoogle Scholar
  65. 65.
    Ichii H, Wang X, Messinger S, et al. Improved human islet isolation using nicotinamide. Am J Transplant. 2006;6(9):2060.PubMedGoogle Scholar
  66. 66.
    Marzorati S, Melzi R, Nano R, et al. In vitro modulation of monocyte chemoattractant protein-1 release in human pancreatic islets. Transplant Proc. 2004;36(3):607.PubMedGoogle Scholar
  67. 67.
    Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes. 2002;51(1):55.PubMedGoogle Scholar
  68. 68.
    Bertuzzi F, Marzorati S, Maffi P, et al. Tissue factor and CCL2/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients. J Clin Endocrinol Metab. 2004;89(11):5724.PubMedGoogle Scholar
  69. 69.
    Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia. 2001;44(3):325.PubMedGoogle Scholar
  70. 70.
    Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation. 2003;76(9):1285.PubMedGoogle Scholar
  71. 71.
    Ichii H, Sakuma Y, Pileggi A, Fraker C, Alvarez A, Montelongo J, et al. Shipment of human islets for transplantation. Am J Transplant. Apr 2007;7(4):1010–20.Google Scholar
  72. 72.
    Goss JA, Goodpastor SE, Brunicardi FC, et al. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation. 2004;77(3):462.PubMedGoogle Scholar
  73. 73.
    Kempf MC, Andres A, Morel P, et al. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation. 2005;79(9):1200.PubMedGoogle Scholar
  74. 74.
    Kessler L, Bucher P, Milliat-Guittard L, et al. Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL network. Transplantation. 2004;77(8):1301.PubMedGoogle Scholar
  75. 75.
    Brunicardi FC. Clinical islet transplantation: a consortium model. Transplant Proc. 1996;28(4):2138.PubMedGoogle Scholar
  76. 76.
    Brunicardi FC, Atiya A, Stock P, et al. Clinical islet transplantation experience of the University of California islet transplant consortium. Surgery. 1995;118(6):967.PubMedGoogle Scholar
  77. 77.
    Rabkin JM, Olyaei AJ, Orloff SL, et al. Distant processing of pancreas islets for autotransplantation following total pancreatectomy. Am J Surg. 1999;177(5):423.PubMedGoogle Scholar
  78. 78.
    Pileggi A, Ricordi C, Kenyon NS, et al. Twenty years of clinical islet transplantation at the Diabetes Research Institute––University of Miami. Clin Transpl. 2004;177.Google Scholar
  79. 79.
    Lee TC, Barshes NR, Brunicardi FC, et al. Procurement of the human pancreas for pancreatic islet transplantation. Transplantation. 2004;78(3):481.PubMedGoogle Scholar
  80. 80.
    Goss JA, Soltes G, Goodpastor SE, et al. Pancreatic islet transplantation: the radiographic approach. Transplantation. 2003;76(1):199.PubMedGoogle Scholar
  81. 81.
    Fraker CA, Alvarez S, Papadopoulos P, et al. Enhanced oxygenation promotes beta-cell differentiation in vitro. Stem Cells. 2007;25(12):3155.PubMedGoogle Scholar
  82. 82.
    Rozak PR, Weegman BP, Avgoustiniatos ES, et al. Devices and methods for maintenance of temperature and pressure during islet shipment. Transplant Proc. 2008;40(2):407.PubMedGoogle Scholar
  83. 83.
    Pileggi A, Alejandro R, Ricordi C. Clinical islet transplantation. Minerva Endocrinol. 2006;31(3):219.PubMedGoogle Scholar
  84. 84.
    Ault A. Edmonton’s islet success tough to duplicate elsewhere. Lancet. 2003;361(9374):2054.PubMedGoogle Scholar
  85. 85.
    London NJ, Contractor H, Lake SP, Aucott GC, Bell PR, James RF. A microfluorometric viability assay for isolated human and rat islets of Langerhans. Diabetes Res. 1989;12(3):141.PubMedGoogle Scholar
  86. 86.
    Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation. 1988;45(4):827.PubMedCrossRefGoogle Scholar
  87. 87.
    Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat. 1990;27(3):185.PubMedGoogle Scholar
  88. 88.
    Ichii H, Inverardi L, Pileggi A, et al. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant. 2005;5(7):1635.PubMedGoogle Scholar
  89. 89.
    Fraker C, Timmins MR, Guarino RD, et al. The use of the BD oxygen biosensor system to assess isolated human islets of langerhans: oxygen consumption as a potential measure of islet potency. Cell Transplant. 2006;15(8–9):745.PubMedGoogle Scholar
  90. 90.
    Papas KK, Colton CK, Nelson RA, et al. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant. 2007;7(3):707.PubMedGoogle Scholar
  91. 91.
    Sweet IR, Gilbert M, Scott S, et al. Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transplant. 2008;8(1):183.PubMedGoogle Scholar
  92. 92.
    Goto M, Holgersson J, Kumagai-Braesch M, Korsgren O. The ADP/ATP ratio: a novel predictive assay for quality assessment of isolated pancreatic islets. Am J Transplant. 2006;6(10):2483.PubMedGoogle Scholar
  93. 93.
    Venturini M, Angeli E, Maffi P, et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology. 2005;234(2):617.PubMedGoogle Scholar
  94. 94.
    Baidal DA, Froud T, Ferreira JV, Khan A, Alejandro R, Ricordi C. The bag method for islet cell infusion. Cell Transplant. 2003;12(7):809.PubMedGoogle Scholar
  95. 95.
    Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant. 2004;13(1):55.PubMedGoogle Scholar
  96. 96.
    Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation. 2005;80(12):1718.PubMedGoogle Scholar
  97. 97.
    Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation. 2004;78(1):172.PubMedGoogle Scholar
  98. 98.
    Villiger P, Ryan EA, Owen R, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant. 2005;5(12):2992.PubMedGoogle Scholar
  99. 99.
    Johansson H, Goto M, Dufrane D, et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation. Am J Transplant. 2006;6(2):305.PubMedGoogle Scholar
  100. 100.
    Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes. 2007;56(8):2008.PubMedGoogle Scholar
  101. 101.
    Ponte GM, Baidal DA, Romanelli P, et al. Resolution of severe atopic dermatitis after tacrolimus withdrawal. Cell Transplant. 2007;16(1):23.PubMedGoogle Scholar
  102. 102.
    Molinari M, Al-Saif F, Ryan EA, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant. 2005;5(11):2799.PubMedGoogle Scholar
  103. 103.
    Kneteman NM, Lakey JR, Wagner T, Finegood D. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation. 1996;61(8):1206.PubMedGoogle Scholar
  104. 104.
    Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab. 2001;3(6):393.PubMedGoogle Scholar
  105. 105.
    Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes. 2003;52(11):2731.PubMedGoogle Scholar
  106. 106.
    Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes. 2006;55(9):2429.PubMedGoogle Scholar
  107. 107.
    Marcelli-Tourvieille S, Hubert T, Moerman E, et al. In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation. 2007;83(5):532.PubMedGoogle Scholar
  108. 108.
    Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int. 2006;19(9):705.PubMedGoogle Scholar
  109. 109.
    Liu C, Noorchashm H, Sutter JA, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med. 2007;13(11):1295.PubMedGoogle Scholar
  110. 110.
    O’Connell PJ, Hawthorne WJ, Holmes-Walker DJ, et al. Clinical islet transplantation in type 1 diabetes mellitus: results of Australia’s first trial. Med J Aust. 2006;184(5):221.PubMedGoogle Scholar
  111. 111.
    Oberholzer J, Triponez F, Mage R, et al. Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. Transplantation. 2000;69(6):1115.PubMedGoogle Scholar
  112. 112.
    Lehmann R, Weber M, Berthold P, et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant. 2004;4(7):1117.PubMedGoogle Scholar
  113. 113.
    Berney T, Buhler LH, Morel P. Pancreas allocation in the era of islet transplantation. Transpl Int. 2005;18(7):763.PubMedGoogle Scholar
  114. 114.
    Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54(1):100.PubMedGoogle Scholar
  115. 115.
    Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant. 2007;7(2):303.PubMedGoogle Scholar
  116. 116.
    Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation. 2007;84(11):1413.PubMedCrossRefGoogle Scholar
  117. 117.
    Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant. 2007;7(5):1242.PubMedGoogle Scholar
  118. 118.
    Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation. 2006;82(2):180.PubMedGoogle Scholar
  119. 119.
    Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant. 2004;4(3):295.PubMedGoogle Scholar
  120. 120.
    Rabkin JM, Leone JP, Sutherland DE, et al. Transcontinental shipping of pancreatic islets for autotransplantation after total pancreatectomy. Pancreas. 1997;15(4):416.PubMedGoogle Scholar
  121. 121.
    Poggioli R, Inverardi L, Ricordi C. Islet xenotransplantation. Cell Transplant. 2002;11(2):89.PubMedGoogle Scholar
  122. 122.
    Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1, 3-galactosyltransferase-deficient pigs. Science. 2003;299(5605):411.PubMedGoogle Scholar
  123. 123.
    Bottino R, Balamurugan AN, Smetanka C, et al. Isolation outcome and functional characteristics of young and adult pig pancreatic islets for transplantation studies. Xenotransplantation. 2007;14(1):74.PubMedGoogle Scholar
  124. 124.
    Rood PP, Buhler LH, Bottino R, Trucco M, Cooper DK. Pig-to-nonhuman primate islet xenotransplantation: a review of current problems. Cell Transplant. 2006;15(2):89.PubMedGoogle Scholar
  125. 125.
    Diamond LE, Quinn CM, Martin MJ, Lawson J, Platt JL, Logan JS. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation. 2001;71(1):132.PubMedGoogle Scholar
  126. 126.
    Tseng YL, Moran K, Dor FJ, et al. Elicited antibodies in baboons exposed to tissues from alpha1, 3-galactosyltransferase gene-knockout pigs. Transplantation. 2006;81(7):1058.PubMedGoogle Scholar
  127. 127.
    Cruise GM, Hegre OD, Lamberti FV, et al. In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. Cell Transplant. 1999;8(3):293.PubMedGoogle Scholar
  128. 128.
    Gazda LS, Adkins H, Bailie JA, et al. The use of pancreas biopsy scoring provides reliable porcine islet yields while encapsulation permits the determination of microbiological safety. Cell Transplant. 2005;14(7):427.PubMedGoogle Scholar
  129. 129.
    Safley SA, Kapp JA, Weber CJ. Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs. Cell Transplant. 2002;11(7):695.PubMedGoogle Scholar
  130. 130.
    Sigrist S, Mechine-Neuville A, Mandes K, et al. Influence of VEGF on the viability of encapsulated pancreatic rat islets after transplantation in diabetic mice. Cell Transplant. 2003;12(6):627.PubMedGoogle Scholar
  131. 131.
    Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med. 2006;12(3):301.PubMedGoogle Scholar
  132. 132.
    Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med. 2006;12(3):304.PubMedGoogle Scholar
  133. 133.
    Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49(2):157.PubMedGoogle Scholar
  134. 134.
    Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 2001;292(5520):1389.PubMedGoogle Scholar
  135. 135.
    Yang L, Li S, Hatch H, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA. 2002;99(12):8078.PubMedGoogle Scholar
  136. 136.
    Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 2003;302(5648):1223.PubMedGoogle Scholar
  137. 137.
    Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003;111(6):843.PubMedGoogle Scholar
  138. 138.
    De Coppi P, Bartsch G Jr, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25(1):100.PubMedGoogle Scholar
  139. 139.
    Bouwens L, Pipeleers DG. Extra-insular beta cells associated with ductules are frequent in adult human pancreas. Diabetologia. 1998;41(6):629.PubMedGoogle Scholar
  140. 140.
    Yatoh S, Dodge R, Akashi T, et al. Differentiation of affinity-purified human pancreatic duct cells to beta-cells. Diabetes. 2007;56(7):1802.PubMedGoogle Scholar
  141. 141.
    Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med. 2000;6(3):278.PubMedGoogle Scholar
  142. 142.
    Bonner-Weir S, Taneja M, Weir GC, et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA. 2000;97(14):7999.PubMedGoogle Scholar
  143. 143.
    Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26(4):443.PubMedGoogle Scholar
  144. 144.
    Ricordi C, Edlund H. Toward a renewable source of pancreatic beta-cells. Nat Biotechnol. 2008;26(4):397.PubMedGoogle Scholar
  145. 145.
    Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68(10):1613.PubMedGoogle Scholar
  146. 146.
    Knechtle SJ, Pirsch JD H, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003;3(6):722.PubMedGoogle Scholar
  147. 147.
    Rao V, Pirsch JD, Becker BN, Knechtle SJ. Sirolimus monotherapy following Campath-1H induction. Transplant Proc. 2003;35(3 Suppl):128S.PubMedGoogle Scholar
  148. 148.
    Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA. 1999;96(14):8132.PubMedGoogle Scholar
  149. 149.
    Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes. 1999;48(7):1473.PubMedGoogle Scholar
  150. 150.
    Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443.PubMedGoogle Scholar
  151. 151.
    Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770.PubMedGoogle Scholar
  152. 152.
    Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358(4):353.PubMedGoogle Scholar
  153. 153.
    Yasunami Y, Lacy PE, Finke EH. A new site for islet transplantation–a peritoneal-omental pouch. Transplantation. 1983;36(2):181.PubMedGoogle Scholar
  154. 154.
    Rajotte RV, Tighe VM, Warnock GL, Kneteman NM, Finegood DT. New site for islet transplantation in rats–liver-mesentery or liver-omental pouch. Transplant Proc. 1994;26(2):675.PubMedGoogle Scholar
  155. 155.
    Chaffanjon PC, Kenyon NM, Ricordi C, Kenyon NS. Omental anatomy of non-human primates. Surg Radiol Anat. 2005;27(4):287.PubMedGoogle Scholar
  156. 156.
    Kobayashi T, Aomatsu Y, Iwata H, et al. Survival of microencapsulated islets at 400 days posttransplantation in the omental pouch of NOD mice. Cell Transplant. 2006;15(4):359.PubMedGoogle Scholar
  157. 157.
    Rafael E, Tibell A, Ryden M, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant. 2008;8(2):458.PubMedGoogle Scholar
  158. 158.
    Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006;81(9):1318.PubMedGoogle Scholar
  159. 159.
    Juang JH, Bonner-Weir S, Ogawa Y, Vacanti JP, Weir GC. Outcome of subcutaneous islet transplantation improved by polymer device. Transplantation. 1996;61(11):1557.PubMedGoogle Scholar
  160. 160.
    Kawakami Y, Iwata H, Gu Y, et al. Modified subcutaneous tissue with neovascularization is useful as the site for pancreatic islet transplantation. Cell Transplant. 2000;9(5):729.PubMedGoogle Scholar
  161. 161.
    Gu Y, Tabata Y, Kawakami Y, et al. Development of a new method to induce angiogenesis at subcutaneous site of streptozotocin-induced diabetic rats for islet transplantation. Cell Transplant. 2001;10(4–5):453.PubMedGoogle Scholar
  162. 162.
    Kawakami Y, Iwata H, Gu YJ, et al. Successful subcutaneous pancreatic islet transplantation using an angiogenic growth factor-releasing device. Pancreas. 2001;23(4):375.PubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Cell Transplant Center, Diabetes Research InstituteUniversity of Miami Leonard M. Miller School of MedicineMiamiUSA
  2. 2.DeWitt Family Department of SurgeryUniversity of Miami Leonard M. Miller School of MedicineMiamiUSA

Personalised recommendations